Thirona has successfully renewed its ISO 13485 and EU MDR certifications and, for the first time, achieved certification under the Medical Device Single Audit Program (MDSAP).

We are proud to announce the expansion of our Medical Advisory Board with the addition of three world-renowned pulmonologists

A new Thirona–COPD Foundation study will assess AI-derived QCT biomarkers in over 10,000 COPDGene participants to support advanced phenotyping and targeted treatment.

Divestment of Thirona Retina BV to continue focus on pulmonary diseases and expanding within the interventional pulmonology space

To achieve our mission of advancing personalized and tailored approaches to lung disease treatment and care, we are welcoming top clinical experts to Thirona's Medical Advisory Board.

Blackford and Thirona announce a commercial partnership to bring the LungQ™ solution to healthcare professionals via the Blackford Platform.

Voiant and Thirona have entered a global commercial partnership to provide full scope integral services for clinical trials (with AI-powered lung image analysis), building further on several years of a fruitful cooperation.

Thirona has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the latest update of its AI-based clinical software LungQ™ (v3.0.0)

MedTech companies Aidence, Incepto, and Thirona jointly introduce a comprehensive AI-powered software package for lung cancer screening and the analysis of emphysema